Mantle Cell Lymphoma
Conference Coverage
Rituximab vanquished MRD in mantle cell lymphoma
SAN DIEGO – Rituximab can at least temporarily vanquish minimal residual disease in mantle cell lymphoma patients who relapse after induction...
Conference Coverage
VIDEO: Obinutuzumab bests rituximab for PFS in follicular lymphoma
SAN DIEGO – For patients with indolent non-Hodgkin lymphoma, adding rituximab to a standard-combination chemotherapy regimen resulted in...
Conference Coverage
Antibody face-off in follicular lymphoma gives PFS, but not OS, edge to obinutuzumab
SAN DIEGO – Obinutuzumab, a second-generation anti-CD20 antibody touted as the heir apparent to rituximab, offered a PFS edge over rituximab when...
News
Ibrutinib bodes well for relapsed mantle-cell lymphoma
Key clinical point: Ibrutinib significantly improved progression-free survival, compared with temsirolimus in patients with relapsed or refractory...
News
Ki-67 bests cytology, growth pattern as prognostic factor for MCL
Key clinical point: The Ki-67 index was superior to cytology and growth pattern as a prognostic factor in mantle-cell lymphoma (MCL).
News
Lenalidomide plus rituximab achieves 87% response rate
Key clinical point: First-line combination biologic therapy with lenalidomide plus rituximab produced an 87% overall response rate in stage 3 or 4...
Conference Coverage
RBAC500 safe, effective for elderly patients with mantle cell lymphoma
Key clinical point: Reducing the dose of cytarabine from 800 mg/m2 to 500 mg/m2 allowed a regimen of rituximab, bendamustine, and cytarabine to be...
News
Bendamustine regimen may be induction-therapy option in mantle cell lymphoma
Key clinical point: Rituximab plus bendamustine may prove to be an option for induction therapy prior to autologous stem cell transplant in...
Conference Coverage
Swapping bortezomib for vincristine improves PFS in mantle cell lymphoma
Key clinical point: Substituting bortezomib for vincristine may bring clinical benefit to patients with newly diagnosed mantle cell lymphoma who...
Commentary
Drugs approved in 2013
Conference Coverage
ONO-4059 makes waves in heavily pretreated CLL
Major finding: The response rate was 89% overall and 71% for patients with 17p deletion. Data source: A prospective, phase I dose-escalation study...